Testing a new CAR T-cell treatment for kappa cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial studies a lab-made immune therapy (CAR T cells) that targets “kappa” markers on certain lymphomas and CLL/SLL. It’s for people whose cancer has come back or didn’t respond to standard treatments, aiming to improve control of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and able to sign consent for the study and use of your health information.
- You have a confirmed “kappa-positive” cancer (kappa marker on tissue or flow test), and your specific cancer type must fit CLL/SLL or certain B-cell lymphomas.
- Your cancer must be relapsed or refractory after at least the required number of prior treatments (or after stem cell transplant, if applicable).
- You have enough body function to safely receive treatment (blood counts, liver/kidney labs, oxygen level, and heart tests with a sufficient pumping strength).
- You must be able to plan for treatment timing: stop certain therapies close to cell preparation and complete any “bridging” treatment on schedule (if used).
- You can’t be pregnant or breastfeeding, and if you could become pregnant you must use two birth-control methods (or be surgically sterile) during treatment and for 6 months after the trial ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests an anti-CD19 CAR-T cell treatment in adults with specific types of relapsed or treatment-resistant non-Hodgkin lymphoma. It may help by finding and attacking lymphoma cells that carry the CD19 marker, but it’s early-stage and eligibility is strict.
This trial studies a type of lab-made immune cell therapy (CAR T) using cells called CAR-20/19-T. It is for adults with relapsed or refractory B-cell cancers, aiming to reduce or eliminate lymphoma in people whose disease has come back or not responded to standard treatments.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This trial is testing a new treatment called CD19x22 CAR T cells for people with certain types of B-cell lymphoma that have come back or not responded to other treatments. The therapy uses your own immune cells, which are modified in a lab to better attack the cancer.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
This Phase 2 study compares a “point-of-care” CAR T-cell treatment made at the hospital right away versus standard commercial CAR T-cells. It’s for adults with relapsed or refractory large B-cell lymphoma (a type of blood cancer) to see which approach works best and is safe.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.